Edulis is building a bio-inspired polymer-coating platform that colors hair without oxidative bleaching — attacking a $30.86B global hair color market where, per founder diligence, "there are not rigorously trained scientists working in hair cosmetics." The wedge is a muscle-derived adhesive protein tethered to a transparent, pigment-carrying polymer that eliminates the background-color problem underlying every incumbent oxidative system — delivering damage-free, predictable, non-toxic professional color and, longer term, blonding. Distribution mirrors the K18/Olaplex playbook: salon-only via Salon Centric and Cosmoprof, seeded through celebrity colorists and franchise LOIs rather than DTC.
Validation is unusually strong for a pre-seed chemistry bet. As of initial diligence, Edulis had signed 11 salon LOIs including a 875-location Asian franchise (Jawed Habib), had active partnership dialogue with K18, and was moving into a fume-equipped Bay Area lab. The exit signal has since hardened materially: in Q3 2025 the company received multiple acquisition offers at a $30M post, declined, and moved to a fresh raise — an implied ~6× paper markup on SH's $5M-post entry. StoryHouse wrote a $200K check for ~4% plus a 1% share-count kicker (109,850 shares) out of Fund I, a cap-favorable structure given the observed exit optionality.
Timing is favorable: the professional channel — Edulis's beachhead — carries three-quarters of category revenue, and biotech-driven beauty has moved from novelty to acquisition target (Olaplex closed its first-ever biotech acquisition in 2025; L'Oréal absorbed Color Wow). A rigorously scientific, damage-free color platform sits squarely in the strategic sight-lines of every incumbent listed below.
| Player | Positioning | Funding | Edge vs. Edulis |
|---|---|---|---|
| Edulis | Bio-inspired polymer-coating hair color; predictable, non-toxic, non-damaging; pro salon channel | ~$6.3M raised | — |
| Olaplex | Bond-building repair chemistry; public co.; first-ever biotech acquisition in 2025 to deepen R&D | Public (NASDAQ: OLPX) | Patent estate, distribution scale, salon relationships |
| K18 | Peptide-based bond repair; hot pro brand; explored partnership/investment with Edulis pre-patent | PE/strategic-backed | Brand momentum, pro colorist community, established distribution |
| Madison Reed | DTC + salon hybrid color brand; growth-equity backed incl. MarcyPen (Jay-Z fund) referenced as network | Growth-equity backed | Consumer brand, retail footprint — different chemistry lane |
| Hairprint | Nearest DTC "natural chemistry" analogue; failed to gain widespread traction per founder diligence | Small/private | Cautionary tale on wrong channel — Edulis avoids DTC pitfalls |
Moat: A pending patent estate on a muscle-adhesive-protein-plus-pigment-pacifying-agent coating gives Edulis genuinely novel chemistry in a category where the only comparable IP (Olaplex, K18) is aggressively defended, and where strategic buyers have shown willingness to acquire rather than build.
Likely acquirers are the same category of strategics Estes identified in his 2023-08-15 diligence framing — a "$10–30B market with 5 big buyers who would bid against each other": L'Oréal (recent Color Wow acquisition), Unilever, Estée Lauder, Coty, and Olaplex itself (now buying biotech). Return math: SH's $200K at ~5% blended ownership sees ~$1.5M today on the declined $30M offer alone; a strategic sale at $500M–$1B (in line with pro-hair "damage-free" comps) would return $25M–$50M gross to the check — a meaningful contributor for Fund I.
Met with Brian Eckhardt today who invests out of MarcyPen which is Jay-Z's fund.
They primarily do growth equity but like the beauty category and are investors in Madison Reed.
Brian mentioned liking Edulis and this could be an interesting potential partner/network for Edulis to tap into.
LinkedIn: https://www.linkedin.com/in/beckhardt/
Conversation with Matt. Matt is getting a good comfort level that what needs to happen at the science level will happen. She is bright, she is organized, and unlike most scientists, she has some managerial and marketing potential.
Should the science come out as relevant, it's a $10–30B market that is ripe for disruption; 5 big buyers if you can disrupt it who would bid against each other to buy it. She doesn't have the need to be the IPO CEO, she just wants her science to be the market standard; this is attractive from a founder and business outcome perspective.
If she and her partner can focus and get the science right, then she needs an experienced commercial operator to guide them — she doesn't know what she doesn't know; and the embedded operators are really skilled and highly motivated not to lose billions of profits. They'll try and squash her when she comes to market, and if they aren't successful, a bidding war will commence.
If the science is de-risked in 18 months, and they're ready to GTM, do effective guerrilla marketing in a geography, make it go viral (which he thinks it can), you can build a proven proof-point at a geography level. This could easily sell for $1B+, because whoever gets it will have a major leg on the other players.
This is all beyond her experience; Matt is highly experienced. Coaching her and making sure she gets the right hire at the right time, and if it's starting to go, he could jump in for a year, be the CEO running it, developing the team, giving credibility to it, then step into an executive chair role, grow it and lead it towards trade sale — and he can do it shorter or longer depending on what's good for the business. This is in the higher-multiple return bucket versus other opportunities.
The IndieBio SF lab doesn't have a fume hood; there wasn't any precedent for a team working in one city and coming over for other events. They offered an option for her to fly out to NYC every two weeks. Their valuation is $2.45M.
She'd consider moving to NYC for four months but needs to discuss that with Claudia. Terms: $275K, of which $200K is cash and $75K is program cost, at 11.2%; later, at the end of the program, they inject $250K at a $6M pre-money.
Perception of IndieBio's value add: #1 accelerator for early-stage biotech — lab space, community, ability to capitalize on serendipitous interactions; mentors who have overseen bench-to-market transitions across contexts (YC probably couldn't offer this). She's trying to figure out how valuable this is.
She has a great second option for lab space: has fume hood; everything she needs; $2.5K per month; will get a membership to use Stanford's equipment.
Summary: IndieBio offer doesn't sound that great. Too expensive, too painful to fly out to NYC; lab space isn't a strong value prop in the face of her attractive lab space.